As depicted in Figure 2 and supplementary material, Table S2, 214 carcinomas showed TROP2 expression (IRS ≥ 2, 20.3%), whereas 838 carcinomas were entirely negative or showed very weak expression in single cells (IRS 0–1, 79.7%) and were, therefore, labelled as TROP2 negative. Here, TACSTD2 is linked to carcinoma.